Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19523396 | 0.95 | ELANE (0.48) | ELANEMEN1KMT2AAVPR1BCTSK | |
| SCHEMBL19523397 | 0.95 | ELANE (0.48) | ELANEMEN1KMT2AAVPR1BCTSK | |
| SCHEMBL19502936 | 0.93 | ELANE (0.48) | ELANEMEN1KMT2AAVPR1BCTSK | |
| SCHEMBL19523412 | 0.93 | ELANE (0.48) | ELANEMEN1KMT2AAVPR1BCTSK | |
| SCHEMBL21835813 | 0.91 | ELANE (0.49) | ELANEMEN1KMT2AAVPR1BCYP3A4 | |
| SCHEMBL21835812 | 0.91 | ELANE (0.49) | ELANEMEN1KMT2AAVPR1BCYP3A4 | |
| SCHEMBL22562860 | 0.90 | ELANE (0.51) | ELANEMEN1KMT2AAVPR1BCTSK | |
| SCHEMBL21860387 | 0.89 | ELANE (0.49) | ELANEMEN1KMT2AAVPR1BCTSK | |
| SCHEMBL19523415 | 0.88 | ELANE (0.50) | ELANEMEN1KMT2AAVPR1BCTSK | |
| SCHEMBL19523399 | 0.88 | ELANE (0.51) | ELANEMEN1KMT2AAVPR1BCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| US-20180009787-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-11 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023558-B2 | Compounds | SERPINB1, ELANE, MPO | ELANE 2/4885MEN1 3964/4885KMT2A 3935/4885 |
| US-20180009787-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885MEN1 4581/4885KMT2A 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.